Treatment Options: Immunosuppressants and Antifibrotics

Deciding on a treatment plan for RA-ILD involves a careful balancing act. Because this condition involves both an overactive immune system and the potential for lung scarring, your doctors must decide whether to focus on calming inflammation, slowing down scarring, or doing both at once ^[1][2]. Do not stop or change your RA medications without discussing it with your care team first.

Current standards of care, including the 2023 ACR/CHEST guidelines, emphasize that treatment should be personalized based on your specific “phenotype”—how much active inflammation versus permanent scarring is visible on your scans, and how the disease is behaving clinically ^[3][1].

Controlling the Immune System: Immunosuppressants

The first goal of treatment is often to “turn down” the immune system to prevent it from further attacking the lung tissue. The 2023 guidelines conditionally recommend several options as first-line treatments, and observation may be used for stable or subclinical disease ^[3]:

• Mycophenolate (CellCept): Often used as a first-line choice, this medication helps dampen the immune response ^[3].
• Azathioprine (Imuran): Another common option that works by interfering with the growth of immune cells ^[3].
• Rituximab (Rituxan): This is a biologic infusion that targets specific B-cells in the immune system ^[3].
• Cyclophosphamide: An option conditionally recommended in certain SARD-ILD settings ^[3].

In some studies, patients on these medications saw their lung function stabilize or even slightly improve compared to their previous trajectory ^[4].

The Role of Glucocorticoids (Steroids)

Glucocorticoids (such as prednisone) are often used in the short term to quickly quiet intense inflammation or during a sudden “flare” ^[3][5]. However, the guidelines are clear: long-term use of steroids is generally recommended against ^[3]. This is because high doses over a long period can lead to serious side effects and significantly increase your risk of dangerous infections ^[6].

Slowing Down Scarring: Antifibrotics

If your lung disease exhibits a “progressive fibrosing phenotype”—meaning it continues to worsen despite being managed—your doctor may add an antifibrotic medication like nintedanib (Ofev) ^[3].

• How it works: Unlike immunosuppressants, nintedanib targets the chemical signals that tell the body to build scar tissue ^[7].
• The Benefit: In a major clinical trial of a progressive fibrosing subgroup, nintedanib was shown to reduce the relative rate of lung function decline by about 59% compared to placebo ^[7]. This is a relative reduction for the study group, not a guarantee that 59% of patients improve.
• The Limitation: It is important to know that nintedanib does not reverse existing scars; its job is to slow down the formation of new ones ^[7].
• Side Effects: The most common side effect is diarrhea, which affected over 60% of patients in the trials ^[7]. It can also affect liver function, so regular blood tests are required to monitor your liver enzymes ^[8].

Understanding the Risks and Comparing Medications

All effective treatments for RA-ILD come with risks that you and your doctor must manage together.

1. Infection Risk: Because most of these drugs (especially rituximab, mycophenolate, and steroids) suppress your immune system, you are at a higher risk for infections ^[6]. This is why staying up to date on vaccinations is critical ^[6].
2. Monitoring: Most of these medications require frequent blood work to ensure your liver, kidneys, and white blood cell counts remain in a healthy range ^[8][6].
3. Individualized Balance: There is no “one size fits all” sequence for these drugs. Your team will look at your FVC (lung volume) and DLCO (oxygen transfer) scores over time. If your FVC drops significantly, it is often a prompt for clinical review to check for infections or other causes before deciding if your current treatment needs to be intensified or changed ^[9].